These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3950069)

  • 1. Variable dose studies provide misleading therapeutic windows.
    Van Putten T; Marder SR
    J Clin Psychopharmacol; 1986 Feb; 6(1):55-6. PubMed ID: 3950069
    [No Abstract]   [Full Text] [Related]  

  • 2. Review of haloperidol blood level and clinical response: looking through the window.
    Volavka J; Cooper TB
    J Clin Psychopharmacol; 1987 Feb; 7(1):25-30. PubMed ID: 3546403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RBC and plasma levels of haloperidol and clinical response in schizophrenia.
    Smith RC; Vroulis G; Shvartsburd A; Allen R; Lewis N; Schoolar JC; Chojnacki M; Johnson R
    Am J Psychiatry; 1982 Aug; 139(8):1054-6. PubMed ID: 7091432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between plasma haloperidol concentrations and clinical results.
    Palao DJ; Araúxo A; Haro JM; Brunet M; Bernardo M
    Arch Gen Psychiatry; 1996 Dec; 53(12):1167-9. PubMed ID: 8956684
    [No Abstract]   [Full Text] [Related]  

  • 5. Haloperidol dose, plasma levels, and clinical response: a double-blind study [proceedings].
    Ericksen SE; Hurt SW; Chang S
    Psychopharmacol Bull; 1978 Apr; 14(2):15-6. PubMed ID: 349597
    [No Abstract]   [Full Text] [Related]  

  • 6. Blood levels of haloperidol and clinical outcome in schizophrenia.
    Doddi S; Rifkin A; Karajgi B; Cooper T; Borenstein M
    J Clin Psychopharmacol; 1994 Jun; 14(3):187-95. PubMed ID: 8027415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of optimal doses of a neuroleptic: preliminary results.
    Potkin SG; Urbanchek MS; Kirch DG; Bunney WE
    Clin Neuropharmacol; 1986; 9 Suppl 4():437-9. PubMed ID: 2882848
    [No Abstract]   [Full Text] [Related]  

  • 8. Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients.
    Hollister LE; Kim DY
    Am J Psychiatry; 1982 Nov; 139(11):1466-8. PubMed ID: 7137396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variable dose studies provide misleading therapeutic windows.
    Van Putten T; Marder SR
    J Clin Psychopharmacol; 1986 Aug; 6(4):249-50. PubMed ID: 3734148
    [No Abstract]   [Full Text] [Related]  

  • 10. Haloperidol plasma levels and clinical response: a therapeutic window relationship.
    Van Putten T; Marder SR; Mintz J; Poland RE
    Psychopharmacol Bull; 1988; 24(1):172-5. PubMed ID: 3387519
    [No Abstract]   [Full Text] [Related]  

  • 11. Reduced haloperidol plasma concentration and clinical response in acute exacerbations of schizophrenia.
    Kelly MW; Perry PJ; Coryell WH; Miller DD; Arndt SV
    Psychopharmacology (Berl); 1990; 102(4):514-20. PubMed ID: 2096408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of the therapeutic effects between haloperidol and insulin coma in schizophrenia and optimal blood levels of haloperidol].
    Shu L
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1987 Feb; 20(1):43-8. PubMed ID: 3304870
    [No Abstract]   [Full Text] [Related]  

  • 13. An open trial of buspirone added to neuroleptics in schizophrenic patients.
    Goff DC; Midha KK; Brotman AW; McCormick S; Waites M; Amico ET
    J Clin Psychopharmacol; 1991 Jun; 11(3):193-7. PubMed ID: 2066458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond the therapeutic window: a case presentation.
    Schulz SC; Butterfield L; Garicano M; Narasimhachari N; Friedel RO
    J Clin Psychiatry; 1984 May; 45(5):223-5. PubMed ID: 6725212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haloperidol levels and clinical response.
    Cohen BM; Baldessarini RJ
    Am J Psychiatry; 1981 Nov; 138(11):1513-4. PubMed ID: 7294231
    [No Abstract]   [Full Text] [Related]  

  • 16. Absence of relationship of serum haloperidol concentration and clinical response in chronic schizophrenia: a fixed-dose study.
    Bigelow LB; Kirch DG; Braun T; Korpi ER; Wagner RL; Zalcman S; Wyatt RJ
    Psychopharmacol Bull; 1985; 21(1):66-8. PubMed ID: 3983341
    [No Abstract]   [Full Text] [Related]  

  • 17. Haloperidol metabolism and antipsychotic effect in schizophrenia.
    Altamura AC; Mauri MC; Cavallaro R; Gorni A
    Lancet; 1987 Apr; 1(8536):814-5. PubMed ID: 2882227
    [No Abstract]   [Full Text] [Related]  

  • 18. Plasma levels of haloperidol and clinical response.
    Van Putten T; Marder SR; May PR; Poland RE; O'Brien RP
    Psychopharmacol Bull; 1985; 21(1):69-72. PubMed ID: 3920705
    [No Abstract]   [Full Text] [Related]  

  • 19. Advantages and disadvantages of depot-neuroleptics as maintenance medication for chronic schizophrenics.
    Möller HJ; Kissling W
    Clin Neuropharmacol; 1986; 9 Suppl 4():259-62. PubMed ID: 2882841
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical response and plasma haloperidol levels in schizophrenia.
    Mavroidis ML; Kanter DR; Hirschowitz J; Garver DL
    Psychopharmacology (Berl); 1983; 81(4):354-6. PubMed ID: 6419263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.